The KIT inhibitors market remains highly competitive, driven by established players such as ONO Pharmaceutical and Blueprint Medicines, among others. At the same time, companies like Celldex ...

The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...

Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing important ...

ASCO 2025 showcased breakthroughs in sarcoma treatment, emphasizing precision medicine, immunotherapy, and promising new ...

The public-interest art exhibition in a Beijing bookstore is dedicated to raising awareness on tenosynovial giant cell tumor, a rare joint disorder. LI HENG/XINHUA In the courtyard of Beijing's ...

TURALIO Ⓡ (pexidartinib) is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not ...

Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor ...

Global Phase 3 MANEUVER study of pimicotinib in tenosynovial giant cell tumor (TGCT) met the primary endpoint, demonstrating objective response rate at week 25 of 54.0% versus 3.2% for placebo ...

Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor Wednesday, May 28, 2025 5:36PM IST ...

Multicenter phase II study of anlotinib and toripalimab in patients with advanced soft tissue sarcoma (STS) and bone sarcoma (BS). Long-term clinical outcome assessments in patients with tenosynovial ...

Emactuzumab, a humanized immunoglobulin G1 monoclonal antibody, targets the CSF-1 receptor and inhibits macrophages in tumor tissue.